ClinicalTrials.gg
RecruitingNCT07378553INNOVANUpdated Jun 24, 2026

Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies

An observational study in Duchene Muscular Dystrophy and Becker Muscular Dystrophy, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to male participants aged 5 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Nantes University Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60
Ages
5 Years to 60 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Muscular Dystrophy, Duchenne with a site in France — 11 open to participants now, 13 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · France.

Planned enrollment
12th of 15
60 · median 220
Started
2026
with 4 others
Observational
15 of 66
4 open now
Primary completion
2029-03
later than 6 of 12 live
Registered
62nd of 66
by date

Among the 66 studies in Muscular Dystrophy, Duchenne with a site in France, this one is the 12th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 62nd registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

11 of the 66 studies in Muscular Dystrophy, Duchenne with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 5 Years to 60 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Muscular Dystrophy, Duchenne with a site in France, or all of them as a file.
02

Study summary

The purpose of this research study is to determine the potential of a multiparametric ultrasound approach to non-invasively monitor disease progression and to serve as an objective outcome measure for future clinical trials in Duchenne and Becker Muscular Dystrophies.

The investigators will compare the muscles of ambulatory or non-ambulatory boys/men with Duchenne and Becker Dystrophies with muscles of healthy age-matched individuals of the same age and monitor disease progression in those with muscular dystrophies over a 12-month year period.

The ultrafast ultrasound technology used in this study allows the simultaneous assessment of muscle structure, mechanics and physiology, including stiffness, anisotropy, viscosity, intramuscular fat, muscle volume, and microvascular perfusion. The amount of muscle alteration measured will be related to performance in daily activities, such as walking and muscle strength, in order to identify sensitive and objective markers of disease progression.

Read the detailed description

Duchenne and Becker muscular dystrophies (DMD/BMD) are the most common forms of muscular dystrophies, progressive muscle wasting diseases leading to weakness and devastating functional impairment. DMD is characterized by predominant involvement in skeletal, including respiratory, and cardiac muscles. Diagnosis is usually established at three to four years of age. Patients typically show muscle degeneration that worsens with age, leading to wheelchair dependency usually by the age of ten, assisted ventilation before the age of twenty, and premature death in the second to fourth decade. BMD shows a similar clinical phenotype but a later onset (approximately twelve years of age), a slower disease progression, delayed or no loss of ambulation, and variable involvement of the cardiac and respiratory systems. Considerable heterogeneity has been observed within and across the DMD/BMD phenotypes, which makes the design and analysis of clinical trials and prediction of the disease progression challenging.

Recent inconsistent results in DMD clinical development programs have also raised questions about the validity of the methods used to evaluate treatment efficacy. The number of potentially effective therapeutic approaches for DMD/BMD has rapidly increased over recent years, and thus the demand for validated outcome measures to demonstrate clinically meaningful therapeutic response over time in clinical trials (e.g., one year) is higher than ever. Regulatory agencies (e.g., FDA) have explicitly been encouraging the development of imaging biomarkers that may serve as surrogate markers of how patients will respond to investigational treatments in DMD/BMD.

This study aims to validate the potential of innovative ultrasound imaging methods, developed by our research consortium over recent years, as imaging tools to monitor disease progression and serve as a surrogate outcome measure for clinical trials in muscular dystrophies. Using cutting-edge ultrasound imaging techniques, including shear wave elastography, matrix approach, 3D freehand ultrasound, and power Doppler we will quantify much needed surrogate measures of muscle damage and progressive degeneration such as intramuscular fat content, fibrosis, muscle apoptosis and structural disorganization, inflammation, hypertrophy/atrophy, and intramuscular blood flow, in the lower and upper extremity muscles. An easy-to-apply multiparametric approach will be developed to assess the most important hallmarks of muscle degeneration associated with the most common and devastating muscular dystrophies.

03

Conditions studied

  • Duchene Muscular Dystrophy
  • Becker Muscular Dystrophy

Keywords

  • Duchenne Muscular Dystrophy
  • Becker Muscular Dystrophy
  • Ultrasound Imaging
  • Ultrafast Ultrasound
  • Muscle
04

Who can participate

Ages eligible
5 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Study Population

This bicentric study will include 60 participants:

18 male patients with Duchenne Muscular Dystrophy (DMD), aged 5 to 30 years (ambulant and non-ambulant),

18 male patients with Becker Muscular Dystrophy (BMD), aged 5 to 60 years,

and 24 healthy male subjects, aged 5 to 60 years, without neuromuscular disease or limb injury.

All participants must have French social insurance coverage and provide informed consent (from parents or legal representatives for minors).

Patients will be recruited mainly from the CHU de Nantes, the Institut de Myologie (Paris), and through the French Muscular Dystrophy Association (AFM-Téléthon). Healthy volunteers will be recruited from Nantes University staff, students, and their children.

The inclusion of minors is necessary because Duchenne and Becker muscular dystrophies are X-linked genetic disorders diagnosed in childhood, and disease severity increases with age.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion Criteria for patients with Duchenne Muscular Dystrophy: Ambulatory and non-ambulatory males (ages 5-30 at baseline testing) previously diagnosed with Duchenne Muscular Dystrophy based on absence of dystrophin expression.
  • Inclusion Criteria for patients with Becker Muscular Dystrophy: Ambulatory and non-ambulatory males (ages 5-60 at baseline testing) previously diagnosed with Becker Muscular Dystrophy based on genetically confirmed, reduced or dysfunctional dystrophin.
  • Inclusion Criteria for Aged-matched controls: Ambulatory males (ages 5-60 years) without disease or injury to the lower and/or upper extremities

Exclusion criteria

Exclusion Criteria:

  • Exclusion Criteria for patients with Duchenne and Becker Muscular Dystrophies:

Inability to undergo static exam, missing measurement site (resection/amputation), neurocognitive impairment preventing

  • Exclusion Criteria for Age-matched controls: Any condition affecting muscle metabolism/function, neuromuscular disease, or injury to the lower and/or upper extremities in the past 5 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Age-matched Controls

    Age matched non-affected men, matched for men with Becker and Duchenne Muscular Dystrophies

  • Boys/Men with Duchenne Muscular Dystrophy

    This group will include ambulatory and non-ambulatory boys/men with Duchenne Muscular Dystrophy ranging from 5-30 years old.

  • Boys/Men with Becker Muscular Dystrophy

    This group will include ambulatory and non-ambulatory men with Becker Muscular Dystrophy ranging from 5-60 years old.

06

What researchers measure

Primary outcomes

  1. Baseline mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of muscle stiffness (kPa) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: Baseline

  2. Baseline mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of anisotropy (a.u.) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: Baseline

  3. Baseline mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of viscosity (Np/mm) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: Baseline

  4. Baseline mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of nonlinear elastic parameters (kPa) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: Baseline

  5. Baseline mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of intramuscular fat (m/s) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: Baseline

  6. Baseline mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of intramuscular blood flow (%) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: Baseline

Secondary outcomes

  1. Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of muscle stiffness (kPa) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: 12 months

  2. Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of anisotropy (a.u.) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: 12 months

  3. Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of viscosity (Np/mm) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: 12 months

  4. Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of nonlinear elastic parameters (kPa) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: 12 months

  5. Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of intramuscular fat (m/s) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: 12 months

  6. Change from baseline in mechanical, structural, and physiological muscle ultrasound parameters

    Assessment of intramuscular blood flow (%) in the lower extremity and/or upper extremity muscles across three participant groups

    Time frame: 12 months

  7. Muscle function

    Muscle strength will be evaluated by dynamometry

    Time frame: Baseline and changes from baseline in at 12 months

  8. Functional outcomes

    10-Meter Walk Test in DMD and BMD participants

    Time frame: Baseline and changes from baseline at 12 months

  9. Functional outcomes

    NorthStar Ambulatory Assessment performance in DMD and BMD participants

    Time frame: Baseline and changes from baseline at 12 months

  10. Correlations between ultrasound measures, muscle function and functional outcomes

    In both BMD and DMD, the correlation between each ultrasound imaging parameter \[muscle stiffness (kPa), anisotropy (a.u.), viscosity (Np/mm), nonlinear elastic parameters (kPa), intramuscular fat (m/s), muscle volume (ml), and intramuscular blood flow (%)\] and all functional endpoints \[NorthStar Ambulatory Assessment, 10-Meter Walk Test\] will be determined, as well as the ability of ultrasound measures to predict future change and loss in function.

    Time frame: Through study completion, 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.

Of 52 non-industry observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 120. This study's planned 36 months is close to that.

Counting every sponsor, half of 63 studies reached it within 40 months; a quarter within 12 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Jan 30, 2026
StartActual
Mar 3, 2026
Primary completionEst.
Mar 3, 2029
CompletionEst.
Mar 3, 2029
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07378553
Collaborators
AGENCE NATIONALE DE RECHERCHE
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Mar 3, 2026
Primary completion
Mar 3, 2029 (estimated)
Completion
Mar 3, 2029 (estimated)
Last update
Jun 24, 2026

Study contacts

Yann PEREON
Contact
yann.pereon@chu-nantes.fr
0240083704

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion